Final PRAISE Trial Data Supports Pamrevlumab’s Efficacy, Safety for IPF
Final data from the PRAISE trial support the efficacy and safety of pamrevlumab, an investigational therapy for the treatment of idiopathic pulmonary fibrosis (IPF) being developed by FibroGen. Data showed that into-the-vein (intravenous) infusions of pamrevlumab reduced the decline in respiratory function by 60.3%. It also cut to…